Publikationen

Home/Forschung/Publikationen

2019.

Lazaridis L, Schäfer N, Teuber-Hanselmann S, Blau T, Schmidt T, Oster C, Weller J, Tzaridis TD, Pierscianek D, Keyvani K, Kleinschnitz C, Stuschke M, Scheffler B, Radbruch A, Sure U, Herrlinger U, Kebir S, Glas M (2019) Tumor Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. J Cancer Res Clin Oncol; accepted for publication

Kebir S, Hattingen E, Niessen M, Rauschbach L, Fimmers R, Hummel T, Schäfer N, Lazaridis L, Kleinschnitz C, Herrlinger U, Scheffler B*, Glas M*. Olfactory Function as Independent Prognostic Factor in Glioblastoma. (2019) Neurology; accepted for publication. *shared last

Sood D, Tang-Schomer M, Pouli D, Mizzoni C, Raia N, Tai A, Arkun K, Wu J, Black L, Scheffler B, Georgakoudi I, Steindler D, Kaplan D (2019) 3D Extracellular Matrix Microenvironment in Bioengineered Tissue Models of Primary Pediatric and Adult Brain Tumors. (2019) Nature Communications 10(1):4529. doi: 10.1038/s41467-019-12420-1

Weller J, Tzaridis, Mack F, Steinbach JP, Schlegel U, Hau P, Krex D, Grauer O, Goldbrunner R, Bähr O, Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schäfer N. Health-related quality of life and neurocognitive functioning in the randomised phase III CeTeG/NOA-09 trial for newly diagnosed MGMT-hypermethylated glioblastoma. (2019) The Lancet Oncology; accepted for publication.

Candelario K, Balaj L, Zheng T, Scheffler B; Skog J, Breakefield X, Schuele B, Steindler D (accepted) Exosome/Microvesicle Content is Altered in LRRK2 Mutant iPSC-derived Neural Cells. (2019) J Comp Neurol; accepted for publication.

Di Tacchio M, Macas J, Weissenberger J, Sommer K, Bähr O, Steinbach JP, Senft C, Seifert V, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Scheel AH, Büttner R, Grauer OM, Schittenhelm J, Tabatabai G, Harter PN, Günther S, Devraj K, Plate KH, Reiss Y. Tumor vessel normalization, immunostimulatory reprogramming and improved survival in a preclinical glioblastoma model by combined inhibition of PD-1, Angiopoietin-2 and VEGF. (2019) Cancer Immunology Research; accepted for publication.

Stoppek AK, Kebir S, Junker A, Keyvani K, Zuelow S, Lazaridis L, Schmidt T, Pierscianek D, Stuschke M, Sure U, Kleinschnitz C, Scheffler B, Zimmer L, Glas M (2019) Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: A case report BMC Cancer 19(1):995. doi: 10.1186/s12885-019-6183-2

Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldiks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, Schlegel U, Schmidt-Graf F, Rohde V, Borchers C, Tabatabai G, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M*, Herrlinger U. Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. (in press) J Neurooncol *shared last

Kebir S, Lazaridis L, Weber M, Deuschl C, Stoppek AK, Schmidt T, Mönninghoff C, Blau T, Keyvani K, Umutlu L, Pierscianek D, Forsting M, Stuschke M, Antoch G, Sure U, Kleinschnitz C, Scheffler B, Colletti PM, Rubello D, Hermann K, Glas M. Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma. (2019) Clin Nucl Med 44(6):e375-e381.

Ahmadipour Y, Kaur M, Pierscianek D, Gembruch O, Oppong MD, Mueller O, Jabbarli R, Glas M, Sure U, El Hindy N. (2019) Association of Surgical Resection, Disability, and Survival in Patients with Glioblastoma. J Neurol Surg A Cent Eur Neurosurg 80:262-268.

Shannan B, Matschke J, Chauvistre H, Vogel F, Klein D, Meier F, Westphal D, Bruns J, Rauschenberg R, Utikal J, Forschner A, Berking C, Terheyden P, Dabrowski E, Gutzmer R, Rafei-Shamsabadi D, Meiss F, Heinzerling L, Zimmer L, Livingstone E, Varaljai R, Hoewner A, Horn S, Klode J, Stuschke M, Scheffler B, Marchetto A, Sannino G, Grunewald TGP, Schadendorf D, Jendrossek V, Roesch A (2019) Sequence-dependent cross-resistance of combined radiotherapy plus BRAF(V600E) inhibition in melanoma. Eur J Cancer 109:137-153.

Schafer N, Gielen GH, Rauschenbach LKebir S, Till A, Reinartz R, Simon M, Niehusmann P, Kleinschnitz C, Herrlinger U, Pietsch T, Scheffler BGlas M (2019) Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors. J Transl Med 17:96.

Rauschenbach LKocakavuk E, Pierscianek D, Ahmadipour Y, Kebir SGlas MScheffler B, Sure U, Jabbarli R (2019) Xenografting for disease modeling of intramedullary spinal cord tumors: a systematic review. Spinal Cord. 57(6):439-448. doi: 10.1038/s41393-019-0248-6.

Pierscianek D, Ahmadipour Y, Oppong MD, Rauschenbach LKebir SGlas M, Sure U, Jabbarli R (2019) Blood-Based Biomarkers in High Grade Gliomas: a Systematic Review. Mol Neurobiol.

Kebir S, Weber M, Lazaridis L, Deuschl C, Schmidt T, Monninghoff C, Keyvani K, Umutlu L, Pierscianek D, Forsting M, Sure U, Stuschke M, Kleinschnitz C, Scheffler B, Colletti PM, Rubello D, Rischpler C, Glas M (2019) Hybrid 11C-MET PET/MRI Combined With “Machine Learning” in Glioma Diagnosis According to the Revised Glioma WHO Classification 2016. Clin Nucl Med 44:214-220.

Kebir SRauschenbach L, Radbruch A, Lazaridis L, Schmidt T, Stoppek AK, Pierscianek D, Stuschke M, Forsting M, Sure U, Keyvani K, Kleinschnitz C, Scheffler BGlas M (2019) Regorafenib in patients with recurrent high-grade astrocytoma. J Cancer Res Clin Oncol 145:1037-1042.

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bahr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schafer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M, Neurooncology Working Group of the German Cancer S (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 393:678-688.

Giordano FA, Link B, Glas M, Herrlinger U, Wenz F, Umansky V, Brown JM, Herskind C (2019) Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12. Cancers (Basel) 11.

Giordano FA, Brehmer S, Murle B, Welzel G, Sperk E, Keller A, Abo-Madyan Y, Scherzinger E, Clausen S, Schneider F, Herskind C, Glas M, Seiz-Rosenhagen M, Groden C, Hanggi D, Schmiedek P, Emami B, Souhami L, Petrecca K, Wenz F (2019) Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO): An Open-Label, Dose-Escalation Phase I/II Trial. Neurosurgery 84:41-49.

Ahmadipour Y, Kaur M, Pierscianek D, Gembruch O, Oppong MD, Mueller O, Jabbarli R, Glas M, Sure U, El Hindy N (2019) Association of Surgical Resection, Disability, and Survival in Patients with Glioblastoma. J Neurol Surg A Cent Eur Neurosurg.

2018.

Schaub C, Kebir S, Junold N, Hattingen E, Schafer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bahr O, Kortmann RD, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hanel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M (2018) Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. J Cancer Res Clin Oncol 144:1581-1589.

Schafer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hanel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Niessen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U (2018) Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro Oncol 20:975-985.

Kebir S, Rauschenbach L, Gielen GH, Schafer N, Tzaridis T, Scheffler B, Giordano FA, Lazaridis L, Herrlinger U, Glas M (2018) Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma. J Clin Neurosci 53:255-258.

Deuschl C, Kirchner J, Poeppel TD, Schaarschmidt B, Kebir S, El Hindy N, Hense J, Quick HH, Glas M, Herrmann K, Umutlu L, Moenninghoff C, Radbruch A, Forsting M, Schlamann M (2018) (11)C-MET PET/MRI for detection of recurrent glioma. Eur J Nucl Med Mol Imaging 45:593-601.

Ceccon G, Lazaridis L, Stoffels G, Rapp M, Weber M, Blau T, Lohmann P, Kebir S, Herrmann K, Fink GR, Langen KJ, Glas M, Galldiks N (2018) Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. Eur J Nucl Med Mol Imaging 45:1626-1635.

2017.

Reinartz R, Wang S, Kebir S, Silver DJ, Wieland A, Zheng T, Kupper M, Rauschenbach L, Fimmers R, Shepherd TM, Trageser D, Till A, Schafer N, Glas M, Hillmer AM, Cichon S, Smith AA, Pietsch T, Liu Y, Reynolds BA, Yachnis A, Pincus DW, Simon M, Brustle O, Steindler DA, Scheffler B (2017) Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma. Clin Cancer Res 23:562-574.

Muller A, Jurcoane A, Kebir S, Ditter P, Schrader F, Herrlinger U, Tzaridis T, Madler B, Schild HH, Glas M, Hattingen E (2017) Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma. Cancer Med 6:89-99.

Kebir S, Khurshid Z, Gaertner FC, Essler M, Hattingen E, Fimmers R, Scheffler B, Herrlinger U, Bundschuh RA, Glas M (2017) Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma. Oncotarget 8:8294-8304.

Herrlinger U, Schafer N, Fimmers R, Griesinger F, Rauch M, Kirchen H, Roth P, Glas M, Bamberg M, Martus P, Thiel E, Korfel A, Weller M (2017) Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. J Cancer Res Clin Oncol 143:1815-1821.

Hattingen E, Muller A, Jurcoane A, Madler B, Ditter P, Schild H, Herrlinger U, Glas M, Kebir S (2017) Value of quantitative magnetic resonance imaging T1-relaxometry in predicting contrast-enhancement in glioblastoma patients. Oncotarget 8:53542-53551.